TY  - JOUR
AU  - Senan, S
AU  - Özgüroğlu, M
AU  - Daniel, D
AU  - Villegas, A
AU  - Vicente, D
AU  - Murakami, S
AU  - Hui, R
AU  - Faivre-Finn, C
AU  - Paz-Ares, L
AU  - Wu, Y L
AU  - Mann, H
AU  - Dennis, P A
AU  - Antonia, S J
PY  - 2022
DO  - 10.1016/j.esmoop.2022.100410
UR  - http://hdl.handle.net/10668/22213
T2  - ESMO open
AB  - The phase III PACIFIC trial (NCT02125461) established consolidation durvalumab as standard of care for patients with unresectable, stage III non-small-cell lung cancer (NSCLC) and no disease progression following chemoradiotherapy (CRT). In some...
LA  - en
KW  - chemotherapy
KW  - immunotherapy
KW  - multimodality therapy
KW  - radiation therapy
KW  - surgery
KW  - Antibodies, Monoclonal
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Chemoradiotherapy
KW  - Disease Progression
KW  - Humans
KW  - Lung Neoplasms
TI  - Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial.
TY  - research article
VL  - 7
ER  -